The combination regimen targeting BRAF and MEK inhibition, for instance, encorafenib (BraftoviTM, ENF) plus binimetinib (Mektovi®, BNB), are now recommended as first-line treatment in patients with unresectable or metastatic melanoma with a BRAF V600-activating mutation. Here, MAP2K7 is linked to metastatic melanoma.